Scientists from Vical Inc reported results of a Phase I/II clinical trial in advanced melanoma patients treated with its cancer immunotherapy candidate Allovectin-7 at the 87th annual meeting of the American Association for Cancer Research, held in Washington DC, USA, last week.
The authors (who had collaborated with investigators from the British Columbia Cancer Agency) reported that three of seven patients with advanced melanoma receiving multiple administrations of Allovectin-7 responded with greater than 50% reductions in tumor size of either injected or uninjected tumor lesions. Moreover, the treatment was well-tolerated by all seven patients. Vical is currently conducting multicenter Phase II efficacy clinical studies.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze